MedTrace Logo

Pulmonary Hypertension: Assessment of Cell Therapy

NCT00469027 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2016-10-17

No results posted yet for this study

Summary

The primary objective is to establish the safety of autologous progenitor cell-based gene therapy of heNOS in patients with severe Pulmonary Arterial Hypertension(PAH) refractory to conventional treatment.

Conditions

  • Hypertension, Pulmonary

Interventions

BIOLOGICAL

eNOS transfected EPCs will be delivered via a PA line

incremental dosing over 3 days

Sponsors & Collaborators

  • Unity Health Toronto

    collaborator OTHER

  • Sir Mortimer B. Davis - Jewish General Hospital

    collaborator OTHER

  • Northern Therapeutics

    lead INDUSTRY

Principal Investigators

  • John Granton, MD · St. Michael's Hospital and University Health Network

  • David Langleben, MD · Sir Mortimer B. Davis - Jewish General Hospital

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00469027 on ClinicalTrials.gov